CARM

Carisma Therapeutics (CARM)

Carisma Therapeutics Inc

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:CARM

1 2 3 4 5 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2024/06/15	05:32	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:CARM	Carisma Therapeutics Inc
2024/06/15	05:30	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:CARM	Carisma Therapeutics Inc
2024/06/14	05:30	PR Newswire (US)	Carisma Therapeutics Announces Adjournment of Annual Meeting of Stockholders	NASDAQ:CARM	Carisma Therapeutics Inc
2024/06/06	00:45	Business Wire	CARMILA : Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L.233-8 II du Code de commerce et l’article 223-16 du Règlement général de l’Autorité des marchés financiers	NASDAQ:CARM	Carisma Therapeutics Inc
2024/06/06	00:45	Business Wire	CARMILA: Information Concerning the Total Number of Voting Rights and Share	NASDAQ:CARM	Carisma Therapeutics Inc
2024/05/30	20:30	PR Newswire (US)	Carisma Therapeutics to Participate in the Jefferies Global Healthcare Conference	NASDAQ:CARM	Carisma Therapeutics Inc
2024/05/29	08:39	Edgar (US Regulatory)	Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]	NASDAQ:CARM	Carisma Therapeutics Inc
2024/05/16	20:30	PR Newswire (US)	Carisma Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT-0525, a Novel HER2-Targeting CAR-Monocyte	NASDAQ:CARM	Carisma Therapeutics Inc
2024/05/09	20:52	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:CARM	Carisma Therapeutics Inc
2024/05/09	20:41	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:CARM	Carisma Therapeutics Inc
2024/05/09	20:30	PR Newswire (US)	Carisma Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights	NASDAQ:CARM	Carisma Therapeutics Inc
2024/05/09	00:45	Business Wire	Carmila: Withdrawal of funds for the liquidity contract	NASDAQ:CARM	Carisma Therapeutics Inc
2024/05/09	00:45	Business Wire	Carmila: Réduction des moyens du contrat de liquidité	NASDAQ:CARM	Carisma Therapeutics Inc
2024/05/08	20:30	PR Newswire (US)	Carisma Therapeutics Presents Preclinical Proof of Concept Data Demonstrating the Anti-Fibrotic Potential of Engineered Macrophages at ASGCT 2024	NASDAQ:CARM	Carisma Therapeutics Inc
2024/05/08	00:45	Business Wire	CARMILA : Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L.233-8 II du Code de commerce et l’article 223-16 du Règlement général de l’Autorité des marchés financiers	NASDAQ:CARM	Carisma Therapeutics Inc
2024/05/08	00:45	Business Wire	CARMILA: Information Concerning the Total Number of Voting Rights and Share	NASDAQ:CARM	Carisma Therapeutics Inc
2024/05/06	20:30	PR Newswire (US)	Carisma Therapeutics to Participate in The Citizens JMP Life Sciences Conference	NASDAQ:CARM	Carisma Therapeutics Inc
2024/05/02	20:30	PR Newswire (US)	Carisma Therapeutics Appoints Dr. Eugene P. Kennedy as Chief Medical Officer	NASDAQ:CARM	Carisma Therapeutics Inc
2024/04/25	06:05	PR Newswire (US)	Carisma Therapeutics Announces Upcoming Presentation at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting	NASDAQ:CARM	Carisma Therapeutics Inc
2024/04/25	01:43	Business Wire	Carmila: Launch of a Share Buyback Program for €10 Million	NASDAQ:CARM	Carisma Therapeutics Inc
2024/04/25	01:43	Business Wire	Carmila : Lancement d’un programme de rachat d’actions pour 10 millions d’euros	NASDAQ:CARM	Carisma Therapeutics Inc
2024/04/23	05:35	PR Newswire (US)	Carisma Therapeutics to Present New Data at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting	NASDAQ:CARM	Carisma Therapeutics Inc
2024/04/18	00:45	Business Wire	Carmila : Information financière au 31 mars 2024	NASDAQ:CARM	Carisma Therapeutics Inc
2024/04/18	00:45	Business Wire	Carmila: First-quarter 2024 Financial Information	NASDAQ:CARM	Carisma Therapeutics Inc
2024/04/06	00:45	Business Wire	Carmila: Information Concerning the Total Number of Voting Rights and Share, Provided Pursuant to Article L.233-8 II of the Code de commerce (French Commercial Code) and Article 223-16 of the Règlement général de l’Autorité des marchés financiers	NASDAQ:CARM	Carisma Therapeutics Inc
2024/04/06	00:45	Business Wire	Carmila : Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L.233-8 II du Code de commerce et l’article 223-16 du Règlement général de l’Autorité des marchés financiers	NASDAQ:CARM	Carisma Therapeutics Inc
2024/04/03	20:00	PR Newswire (US)	Carisma Therapeutics to Present at Upcoming Conferences	NASDAQ:CARM	Carisma Therapeutics Inc
2024/04/01	21:35	PR Newswire (US)	Carisma Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results	NASDAQ:CARM	Carisma Therapeutics Inc
2024/04/01	20:00	PR Newswire (US)	Carisma Therapeutics Announces Changes to its Board of Directors	NASDAQ:CARM	Carisma Therapeutics Inc
2024/03/22	06:00	PR Newswire (US)	Carisma Announces Upcoming Presentations at the American Association for Cancer Research (AACR) Annual Meeting	NASDAQ:CARM	Carisma Therapeutics Inc